The FDA has issued warning letters to telehealth companies regarding their marketing of compounded GLP-1s, citing concerns over misleading claims and potential violations of current good manufacturing practices. The number of companies warned is reported to be 30, although the specific details of the warnings and the companies involved are not universally agreed upon. The FDA's actions appear to be part of a broader effort to address issues related to compounding and telehealth marketing practices.